Publicação
Probioxy: redefining the treatment landscape of inflammatory bowel disease - operations and key assets
| datacite.subject.fos | Ciências Sociais::Economia e Gestão | pt_PT |
| dc.contributor.advisor | Arantes-Oliveira, Nuno | |
| dc.contributor.author | Litland, Steinar | |
| dc.date.accessioned | 2025-02-14T08:58:43Z | |
| dc.date.available | 2025-02-14T08:58:43Z | |
| dc.date.issued | 2024-01-17 | |
| dc.date.submitted | 2023-12-20 | |
| dc.description.abstract | ProbiOxy, a biopharmaceutical start-up, is committed to developing the first probiotic treatment for Inflammatory Bowel Disease (IBD) to improve patients' quality of life. Our strategic approach involves securing initial funding, licensing intellectual property, advancing through pre-clinical and clinical trials, growing our patent portfolio, developing the product pipeline, and ultimately achieving acquisition by a prominent pharmaceutical entity. Central to our strategy is securing exclusive licensing of intellectual property from the Calouste Gulbenkian Foundation, allowing comprehensive ownership and strategic partnerships essential for market positioning. We prioritize protecting our intellectual property through patent filings and ongoing innovation to establish a robust portfolio, enhancing our competitiveness. Collaborations with Instituto Gulbenkian de Ciência and Contract Research Organizations accelerate research and clinical trials, ensuring regulatory compliance and market approval. Our diverse Board of Directors and Advisory Board drive innovation and strategic growth, while investor representatives align our strategic direction with market insights. Our financial strategy emphasizes securing venture capital investments to fuel research and development, ensuring prudent financial management aligned with operational milestones. ProbiOxy's dedication to compliance with regulatory standards, guided by partnerships with regulatory and legal experts underpins our commitment to safety and innovation in the probiotic sector. Through meticulous planning, strategic partnerships, and regulatory compliance, ProbiOxy aim to position itself as a leader in revolutionizing intestinal inflammation treatment with probiotics. | pt_PT |
| dc.identifier.tid | 203864395 | pt_PT |
| dc.identifier.uri | http://hdl.handle.net/10362/178991 | |
| dc.language.iso | eng | pt_PT |
| dc.relation | UID/ECO/00124/2013 | pt_PT |
| dc.subject | Probiotics | pt_PT |
| dc.subject | Operations | pt_PT |
| dc.subject | Assets | pt_PT |
| dc.subject | Entrepreneurship | pt_PT |
| dc.title | Probioxy: redefining the treatment landscape of inflammatory bowel disease - operations and key assets | pt_PT |
| dc.type | master thesis | |
| dspace.entity.type | Publication | |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | masterThesis | pt_PT |
| thesis.degree.name | A Work Project, presented as part of the requirements for the Award of a Master’s degree in Management from the Nova School of Business and Economics | pt_PT |